OPTIMIZING OUTCOMES IN PRIMARY BILIARY CHOLANGITIS

Seizing Opportunities to Address Unmet Needs through PPAR Agonists in the Second-line Setting



Guidelines

AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD)

- Practice Guidance Updates for Primary Biliary Cholangitis (2021)
- Practice Guidance for Primary Biliary Cholangitis (2018)

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL)

- Clinical Practice Guidelines for Primary Biliary Cholangitis (2017)

Suggested Readings

Burden of PBC and the Importance of Early Diagnosis and Effective Intervention

Abbas N, Smith R, Flack S, et al. Critical shortfalls in the management of PBC: results of a UK-wide, population-based evaluation of care delivery. *JHEP Rep*. 2023;6(1):100931. doi:10.1016/j.jhepr.2023.100931.

Corpechot C, Lemoinne S, Soret PA, et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? *Hepatology.* 2024;79(1):39–48. doi:10.1097/HEP.0000000000000529.

European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. *J Hepatol*. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022.

Faisal A. Understanding fatigue and pruritus in primary biliary cholangitis. *Clin Liver Dis (Hoboken).* 2024;23(1):e0216. doi:10.1097/CLD.0000000000000216.

Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. *Am J Gastroenterol*. 2020;115(2):262–270. doi:10.14309/ajg.0000000000000512.

Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology.* 2014;147(6):1338-49.e5. doi:10.1053/j.gastro.2014.08.029.

Lindor KD, Bowlus C, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2019;69(1):394–419. doi:10.1002/hep.30145.

Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. *Clin Gastroenterol Hepatol*. 2018;16(8):1342–1350.e1. doi:10.1016/j.cgh.2017.12.033.

Martini F, Balducci D, Mancinelli M, et al. Risk stratification in primary biliary cholangitis. *J Clin Med*. 2023;12(17):5713. doi:10.3390/jcm12175713.

Mayo MJ, Carey E, Smith HT, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis [published correction appears in: *Dig Dis Sci*. 2023;68(10):4064–4065]. *Dig Dis Sci*. 2023;68(3):995–1005. doi:10.1007/s10620-022-07581-x.

Roberts SB, Choi WJ, Worobetz L, et al. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis [published correction appears in: *JHEP Rep.* 2025;7(3):101359]. *JHEP Rep*. 2024;6(10):101168. doi:10.1016/j.jhepr.2024.101168.

Sierra L, Ferrigno B, Marenco-Flores A, et al. Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: a United States cohort. *Ann Hepatol*. 2025;30(2):101945. doi:10.1016/j.aohep.2025.101945.

Tanaka A, Ma X, Takahashi A, Vierling JM. Primary biliary cholangitis. *Lancet.* 2024;404(10457):1053–1066. doi:10.1016/S0140-6736(24)01303-5.

Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. *Hepatol Commun*. 2023;7(6):e0179. doi:10.1097/HC9.0000000000000179.

Yang C, Guo G, Li B, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. *Hepatol Int*. 2023;17(1):237–248. doi:10.1007/s12072-022-10431-7.

You H, Duan W, Li S, et al. Guidelines on the diagnosis and management of primary biliary cholangitis (2021*). J Clin Transl Hepatol*. 2023;11(3):736–746. doi:10.14218/JCTH.2022.00347.

Evolving Second-line Strategies for PBC

Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. *N Engl J Med*. 2018;378(23):2171–2181. doi:10.1056/NEJMoa1714519.

Elafibranor (package insert). Revised June 2024. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf. Accessed May 2026.

Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. *N Engl J Med*. 2024;390(9):783–794. doi:10.1056/NEJMoa2312100.

Hirschfield GM, Kremer AE, Leby C, et al. Sustained and clinically meaningful improvements in moderate to severe pruritus patients with PBC treated with seladelpar: results from the ASSURE study up to 30 months. Abstract 5015. Presented at: American Association for the Study of Liver Diseases, The Liver Meeting 2025; November 7–11, 2025; Washington, DC.

Jones DE, Carbone M, Kremer AE, et al. Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis, with limited correlation with pruritus: analyses from the phase III ELATIVE trial. Abstract LBP-27. Presented at: European Association for the Study of the Liver (EASL) Congress 2025; May 7–10, 2025; Amsterdam, the Netherlands.

Jones DE, Carbone M, Kremer AE, et al**.** Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis. Presented at: American Association for the Study of Liver Diseases, The Liver Meeting 2025; November 7–11, 2025; Washington, DC.

Jones DE, Carbone M, Kremer AE, et al. P26: Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis (PBC), with limited correlation with pruritus: analyses from the phase III ELATIVE trial. *Gut.* 2025;74:A30–A31.

Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. *N Engl J Med.* 2024;390(9):795–805. doi:10.1056/NEJMoa2306185.

Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with PBC. *Gastroenterol Hepatol (N Y)*. 2025;21(12 Suppl 10):3–4.

Martins A, Khakoo NS, Reddy A, et al. Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: a systematic review and network meta-analysis. *Hepatology*. 2026;83(4):721–734. doi:10.1097/HEP.0000000000001465.

Pratt D, Lawitz EJ, Bowlus CL, et al. Seladelpar is associated with a sustained reduction in cholestatic markers and a consistent safety profile in patients with primary biliary cholangitis treated up to 48 months in the ongoing, open-label ASSURE study. *Dig Liver Dis*. 2026;58(Suppl 1):S66–S67. doi:10.1016/j.dld.2026.01.111.

Seladelpar (package insert). Revised January 2026. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217899s002lbl.pdf. Accessed May 2026.

Seladelpar is associated with a sustained reduction in cholestatic markers and a consistent safety profile in patients with PBC treated up to 48 months in the ongoing, open-label ASSURE study. *Gastroenterol Hepatol (N Y)*. 2025;21(12 Suppl 10):2–3

Tanaka A, Hirohara J, Nakano T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. *J Hepatol*. 2021;75(3):565–571. doi:10.1016/j.jhep.2021.04.010.

Wetten A, Jones DEJ, Dyson JK. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). *Expert Opin Investig Drugs*. 2022;31(10):1101–1107. doi:10.1080/13543784.2022.2130750.

Case One

Caines A, Lu M, Wu T, et al. Pre-diagnosis alkaline phosphatase and antimitochondrial antibody positivity vary by race/ethnicity among patients with primary biliary cholangitis. *J Gastroenterol Hepatol*. 2025;40(9):2209–2218. doi:10.1111/jgh.17035.

European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. *J Hepatol*. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022.

Levy C, Bowlus CL. Primary biliary cholangitis: personalizing second-line therapies [published correction appears in: *Hepatology*. 2025;81(5):E150]. *Hepatology.* 2025;82(4):895–910. doi:10.1097/HEP.0000000000001166.

Lindor KD, Bowlus C, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2019;69(1):394–419. doi:10.1002/hep.30145.

Lu M, Li J, Haller IV, et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. *Clin Gastroenterol Hepatol*. 2018;16(8):1333–1341.e6. doi:10.1016/j.cgh.2017.10.018.

Martini F, Balducci D, Mancinelli M, et al. Risk stratification in primary biliary cholangitis. *J Clin Med*. 2023;12(17):5713. doi:10.3390/jcm12175713.

Mimura S, Morishita A, Oura K, et al. Autoantibodies in primary biliary cholangitis: from classical markers to emerging targets. *J Clin Med*. 2025;14(23):8503. doi:10.3390/jcm14238503.

Sohal A, Nikzad N, Kowdley KV. Overlap syndromes in autoimmune liver disease: a review. *Transl Gastroenterol Hepatol*. 2025;10:33. doi:10.21037/tgh-24-140.

Tanaka A, Ma X, Takahashi A, Vierling JM. Primary biliary cholangitis. *Lancet.* 2024;404(10457):1053–1066. doi:10.1016/S0140-6736(24)01303-5.

You H, Duan W, Li S, et al. Guidelines on the diagnosis and management of primary biliary cholangitis (2021*). J Clin Transl Hepatol*. 2023;11(3):736–746. doi:10.14218/JCTH.2022.00347.

Case Two

Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. *Lancet Gastroenterol Hepatol*. 2018;3(9):626–634. doi:10.1016/S2468-1253(18)30163-8.

Efficacy and safety of seladelpar in patients with PBC and compensated cirrhosis in the phase 3 placebo-controlled RESPONSE trial. *Gastroenterol Hepatol (N Y)*. 2024;20(12 Suppl 12):2–3.

Elafibranor (package insert). Revised June 2024. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf. Accessed May 2026.

European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. *J Hepatol*. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022.

Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. *N Engl J Med*. 2024;390(9):783–794. doi:10.1056/NEJMoa2312100.

Hirschfield GM, Kremer AE, Leby C, et al. Sustained and clinically meaningful improvements in moderate to severe pruritus patients with PBC treated with seladelpar: results from the ASSURE study up to 30 months. Abstract 5015. Presented at: American Association for the Study of Liver Diseases, The Liver Meeting 2025; November 7–11, 2025; Washington, DC.

Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. *N Engl J Med.* 2024;390(9):795–805. doi:10.1056/NEJMoa2306185.

Li SX, Li BE, Li M, et al. GLOBE score and UK-PBC risk score predict long-term clinical outcomes of patients with primary biliary cholangitis and receiving ursodeoxycholic acid and fenofibrate. *J Dig Dis*. 2025;26(5–6):250–259. doi:10.1111/1751-2980.13359.

Lindor KD, Bowlus C, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2019;69(1):394–419. doi:10.1002/hep.30145.

Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with PBC. *Gastroenterol Hepatol (N Y)*. 2025;21(12 Suppl 10):3–4.

Roberts SB, Choi WJ, Worobetz L, et al. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis [published correction appears in: *JHEP Rep.* 2025;7(3):101359]. *JHEP Rep*. 2024;6(10):101168. doi:10.1016/j.jhepr.2024.101168.

Seladelpar (package insert). Revised January 2026. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217899s002lbl.pdf. Accessed May 2026.

Yang C, Guo G, Li B, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. *Hepatol Int*. 2023;17(1):237–248. doi:10.1007/s12072-022-10431-7.

Case Three

American Association for the Study of Liver Diseases. AASLD acknowledges withdrawal of obeticholic acid for primary biliary cholangitis and announces upcoming guideline update. Published November 6, 2025. https://www.aasld.org/statement-aasld-aasld-acknowledges-withdrawal-obeticholic-acid-primary-biliary-cholangitis-and. Accessed May 2026.

Brunk D. FDA approves linerixibat for cholestatic pruritus in PBC. *GI & Hepatology News.* Published March 19, 2026. https://news.gastro.org/issues/2026/march/fda-approves-linerixibat-for-cholestatic-pruritus-in-pbc/. Accessed May 2026.

Dean R, Yazdanfar M, Zepeda J, et al. Treatment of pruritus in primary sclerosing cholangitis: analysis of the consortium for autoimmune liver disease registry. *Hepatol Commun*. 2025;9(5):e0703. doi:10.1097/HC9.0000000000000703.

Düll MM, Kremer AE. Evaluation and management of pruritus in primary biliary cholangitis. *Clin Liver Dis*. 2022;26(4):727–745. doi:10.1016/j.cld.2022.06.009.

European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. *J Hepatol*. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022.

Fu X, Xiao Y, Golden J, et al. Serum bile acids profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application on pediatric liver and intestinal diseases. *Clin Chem Lab Med.* 2020;58(5):787–797. doi:10.1515/cclm-2019-0354.

Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial [published correction appears in: *Lancet Gastroenterol Hepatol*. 2026;11(4):e6]. *Lancet Gastroenterol Hepatol*. 2026;11(1):22–33. doi:10.1016/S2468-1253(25)00192-X.

Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. *N Engl J Med*. 2024;390(9):783–794. doi:10.1056/NEJMoa2312100.

Kim DJ, Yoon S, Ji SC, et al. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction [published correction appears in: *Sci Rep*. 2019;9(1):17003]. *Sci Rep*. 2018;8(1):11874. doi:10.1038/s41598-018-30349-1.

Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. *N Engl J Med.* 2024;390(9):795–805. doi:10.1056/NEJMoa2306185.

Kremer AE, Kowdley KV, Levy C, et al. LPB-028 Effect of elafibranor on pruritus in primary biliary cholangitis: symptom severity and quality of life measurements from the phase III ELATIVE trial. *J Hepatol.* 2024;80:S91–S92.

Li N, Zhang X, Li M, et al. Simultaneous determination of UDCA and its major metabolites in human plasma with surrogate matrix by a rapid and specific LC-MS/MS method. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2023;1223:123726. doi:10.1016/j.jchromb.2023.123726.

Lindor KD, Bowlus C, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2019;69(1):394–419. doi:10.1002/hep.30145.

Lindor KD, Lacerda MA, Jorgensen RA, et al. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. *Am J Gastroenterol*. 1998;93(9):1498–1504. doi:10.1111/j.1572-0241.1998.00470.x.

Manzotti C, Casazza G, Stimac T, et al. Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy. *Cochrane Database Syst Rev*. 2019;7(7):CD012546. doi:10.1002/14651858.CD012546.pub2.

Martins A, Levy C. Ileal bile acid transport inhibitors for cholestatic pruritus: a primer. *Curr Hepatol Rep.* 2025;24:28.

Pate J, Gutierrez JA, Frenette CT, et al. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. *BMJ Open Gastroenterol*. 2019;6(1):e000256. doi:10.1136/bmjgast-2018-000256.

Patel SP, Vasavda C, Ho B, et al. Cholestatic pruritus: emerging mechanisms and therapeutics. *J Am Acad Dermatol*. 2019;81(6):1371–1378. doi:10.1016/j.jaad.2019.04.035.

Smith HT, de Souza AR, Thompson AH, et al. Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review. *Dig Dis Sci*. 2023;68(6):2710–2730. doi:10.1007/s10620-023-07862-z.

Trauner M, Karpen SJ, Dawson PA. Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease. *Hepatology*. 2025;82(4):855–876. doi:10.1097/HEP.0000000000001438.

U.S. Food and Drug Administration. Ocaliva (obeticholic acid) by Intercept Pharmaceuticals: Drug Safety Communication—Serious Liver Injury Being Observed in Patients without Cirrhosis. Published December 12, 2024. https://www.fda.gov/safety/medical-product-safety-information/ocaliva-obeticholic-acid-intercept-pharmaceuticals-drug-safety-communication-serious-liver-injury. Accessed May 2026.

You H, Duan W, Li S, et al. Guidelines on the diagnosis and management of primary biliary cholangitis (2021*). J Clin Transl Hepatol*. 2023;11(3):736–746. doi:10.14218/JCTH.2022.00347.